Clover Initiates P-II Trial of COVID-19 Vaccine as Heterologous Booster for the Treatment of COVID-19
- The company initiates a P-II trial in 2 stages to evaluate 3 formulations, immunogenicity & safety of SCB-2019 as a heterologous booster dose in 520 patients with COVID-19 prior vaccinated with CoronaVac or recombinant COVID-19 vaccine at multiple sites in Brazil. The trial is sponsored by IDOR & funded by Bill & Melinda Gates Foundation
- The objective is to determine the optimal vaccine formulation over the homologous booster of a recombinant COVID-19 vaccine. The results are expected in H1’22
- The SPECTRA trial data was reported in Sep 2021 showed that SCB-2019 showed a strong boosting effect on neutralizing Ab titers, favorable safety profile to support COVID-19 vaccine as a booster vaccine
Ref: Globenewswire | Image: Clover
Click here to read the full press release
Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at [email protected].